2018 American Transplant Congress
Immune Modulatory Effect of Thalidomide and Dexamethasone Co-Treatment on Murine Splenocytes
Thalidomide (TM) is known to have anti-inflammatory effects and dexamethasone (DX) is also well known to reduce inflammation and inhibit inflammatory cytokine production. Clinically, combinatorial…2018 American Transplant Congress
Steroid Sparing Maintenance Immunosuppression is Associated with Decreased Mortality after Simultaneous Liver Kidney Transplantation
Purpose: Significant variation in maintenance immunosuppression (mIS) regimens has been described between transplant centers for simultaneous liver kidney (SLK) transplant recipients; we sought to describe…2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…2018 American Transplant Congress
Development of Denovo DSA after One Year Post Kidney Transplant and Clinical Outcomes in Patient on Steroid Free Immunosupression
Background: Development of Denovo donor specific antibodies (DnDSA) has been associated with poor allograft outcomes in few studies. However, there is scarcity of data evaluating…2018 American Transplant Congress
Delayed Graft Function in Live Donor HLA-Incompatible Kidney Transplant Recipients: A Multicenter Study
1JHU, Baltimore; 2UCSF, San Francisco.
Background: Many patients with a willing, but incompatible live donor choose to undergo incompatible live donor kidney transplantation (ILDKT) facilitated by desensitization procedures to eliminate…2018 American Transplant Congress
Evaluation of MPA Dose on Development of DSA Following Pancreas Transplant
The relationship between mycophenolate (MPA) dose and the development of donor specific antibody (DSA) following pancreas transplant has not been elucidated. This study evaluates the…2018 American Transplant Congress
Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and Their Influence on Tacrolimus Pharmacokinetics in Renal Transplant Recipients
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Tacrolimus (TAC) is an established essential immunosuppressive agent for renal transplant recipients. Our study aims to investigate the pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19…2018 American Transplant Congress
Impact of Once-Daily Tacrolimus on Adherence in Stable Adolescent and Young Adult Renal Transplant Recipients
Medication non-adherence is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs), especially adolescents and young adults (AYA). Number of medication…2018 American Transplant Congress
Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Belatacept was shown to have longer kidney graft survival and higher eGFR at 7 years than a calcineurin inhibitor (CNI)-based regimen in the BENEFIT…2018 American Transplant Congress
Cognition after Belatacept Conversion
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 138
- Next Page »